|drug1842||Lopinavir / Ritonavir Wiki||0.45|
|D014777||Virus Diseases NIH||0.10|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The pandemic caused by SARS-CoV-2 is a global emergency present in 6 continents including 66 countries, incurring a shortage of effective and safe therapeutic alternatives that can contribute to reducing the risk of contamination, as well as helping to reduce the viral load of the positive patient. This requires a coordinated, effective and immediate action on the part of governments, companies, academic entities and even at the individual level. In the search for new therapeutic and prevention alternatives, the application of hypochlorous acid (HClO) to the nasal mucosa is proposed, a broad-spectrum and fast-acting antimicrobial solution, whose safety has been proven in preclinical trials. The efficacy of HClO has been tested against enveloped and non-enveloped viruses, reducing virus particles without affecting human cells. This solution could contribute to reducing the viral load and the risk of contamination of patients and professionals. This could have an impact on controlling the COVID-19 pandemic.
Description: Number of participants who get COVID19 infection during the application of S-HClOMeasure: Prevention of infection by COVID19 Time: Through study completion, an average of 6 months
Description: Determine the occurrence of ADR by the use of S-HClOMeasure: Adverse drug reaction (ADR) Time: Through study completion, an average of 6 months
Description: Determine the frequency of seroconversion due to COVID 19Measure: Seroconversion Time: Through study completion, an average of 6 months
Description: Number of participants who fell ill from COVID-19 and was not hospitalizedMeasure: Hospitalization Time: Through study completion, an average of 6 months
Description: Number of participants who fell ill from COVID-19 and was hospitalized in ICUMeasure: ICU Time: Through study completion, an average of 6 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports